A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive report on the, "Mental Health Apps Market Size and ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...